Delving into the Latest Updates on Siegfried Irvine with Synapse

Overview

Tags

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Prostanoid receptor	1

Primary objective: To evaluate the pharmacokinetic characteristics of single and multiple administrations of 0.1% NCX 470 eye drops in healthy Chinese subjects Secondary objective: To evaluate the safety and tolerability of single and multiple administrations of 0.1% NCX 470 eye drops in healthy Chinese subjects

Start Date22 Feb 2023

Sponsor / Collaborator

Nicox Ophthalmics, Inc.

[+2]

CTR20211277

/ RecruitingPhase 3

在开角型青光眼或高眼压症受试者中比较NCX 470与拉坦前列素0.005%的有效性和安全性的研究

[Translation] A Study Comparing the Efficacy and Safety of NCX 470 versus Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension

本研究的主要目的是证明NCX 470滴眼液(0.1%)QD不劣于拉坦前列素滴眼液(0.005%)QD

[Translation]

The primary objective of this study was to demonstrate that NCX 470 eye drops (0.1%) QD is non-inferior to latanoprost eye drops (0.005%) QD

Start Date14 Dec 2021

Sponsor / Collaborator

Nicox Ophthalmics, Inc.

[+2]

CTR20211278

/ CompletedPhase 3

在开角型青光眼或高眼压症受试者中比较NCX 470与拉坦前列素0.005%的有效性和安全性的研究

[Translation] A Study Comparing the Efficacy and Safety of NCX 470 versus Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension

本研究的主要目的是证明NCX 470(0.065%或0.1%)QD在第2周、第6周和第3个月访视时在8AM和4PM时的自时间匹配基线的平均眼内压降低不劣于拉坦前列素0.005% QD。

[Translation]

The primary objective of this study was to demonstrate that NCX 470 (0.065% or 0.1%) QD was noninferior to latanoprost 0.005% QD in reducing mean IOP from a time-matched baseline at 8 AM and 4 PM at the Week 2, Week 6, and Month 3 visits.

Start Date25 Nov 2021

Sponsor / Collaborator

Nicox Ophthalmics, Inc.

[+2]

100 Clinical Results associated with Siegfried Irvine

Login to view more data

0 Patents (Medical) associated with Siegfried Irvine

Login to view more data

100 Deals associated with Siegfried Irvine

Login to view more data

100 Translational Medicine associated with Siegfried Irvine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data